FY2025 · ended Dec 31, 2025 · Revenue $192.22M, -2.5% YoY · Filed Mar 13, 2026
biote Corp. (BTMD) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $192.2 million and net income of $27.0 million. Free cash flow was $30.2 million. As of Jun 30, 2026 it held $11.2 million in cash and investments and $132.1 million in total debt.
Revenue (TTM)
$183.53M
-7.8% vs year-ago TTM
Net income (TTM)
$5.86M
-81.3% vs year-ago TTM
Operating cash flow (TTM)
$24.37M
-41.3% vs year-ago TTM
Free cash flow (TTM)
$19.87M
-42.9% vs year-ago TTM
EPS (TTM)
$0.18
-79.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
58.22M
Net cash
$-120.97M
as of Jun 30, 2026
Operating margin
8.0%
FY 2026
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- BTMD (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Irving, TX
- SEC filer status
- Accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1819253
- Former names
- Haymaker Acquisition Corp. III (until May 25, 2022)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $192.2M | $197.2M | $185.4M | $165.0M | — |
| Operating income | $35.6M | $31.6M | $28.7M | -$60.7M | $34.6M |
| Net income | $27.0M | $3.2M | $3.3M | -$969,000 | $11.1M |
| Diluted EPS | $0.74 | $0.09 | $0.13 | -$0.12 | — |
| Operating cash flow | $35.2M | $45.2M | $26.9M | -$9.2M | $33.7M |
| Free cash flow | $30.2M | $38.8M | $26.5M | -$9.5M | — |
| Total assets | $107.6M | $122.4M | $155.3M | $111.6M | $54.3M |
| Total liabilities | $158.0M | $224.6M | $191.8M | $169.9M | $50.2M |
| Stockholders' equity | -$58.5M | -$105.9M | -$29.4M | -$44.5M | $4.1M |
| Cash and investments | $24.1M | $39.3M | $89.0M | — | $130,359 |
| Total debt | $106.0M | $112.8M | $117.6M | $124.0M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Jun 17, 2026 | Jun 12, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 2, 2026 | May 27, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 18, 2026 | May 12, 2026 |
All 411 biote Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.